TP53 and diffuse large B-cell lymphoma: In DLBCL, TP53 gene alterations, including TP53 mutations and/or del(17p), are detected in approximately 30–50% of patients and mostly result in inferior outcome upon treatment with rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP)13,14,23.